Bolt Biotherapeutics, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $22.
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Bolt Biotherapeutics Inc:Bolt Biotherapeutics reports first quarter 2026 financial results and provides business update...
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the analyst consensus estimate of $(2.85) by 51.23 percent. This is a 25.69 percent increase over losses of $(5.80) per share
REDWOOD CITY, Calif. — REDWOOD CITY, Calif. — Bolt Biotherapeutics Inc. on Tuesday reported a loss of $7.2 million in its first quarter. On a per-share basis, the Redwood City,...
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund...
Study Design: Dose Escalation with Cycle 1 Step-Up Dosing Backfill at dose levels cleared for safety Gastric and gastroesophageal cancer patients ...
VANCOUVER, BC / ACCESS Newswire / April 9, 2026 /Bolt Metals Corp. ("Bolt" or the "Company") (TSXV:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), a North American mineral acquisition and exploration company, is pleased to announce the appointment of Mr. Rick Mah ...
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
BOLT) on Thursday reported a loss of $6.6 million in its fourth quarter. The Redwood City, California-based company said it had a loss of $3.84 per share. The company posted revenue of $2.5 million in the period.
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(3.84) per share which beat the analyst consensus estimate of $(4.30) by 10.7 percent. This is a 49.47 percent increase over losses of $(7.60) per share
https://x.com/PatentGrants/status/1998150771544928598?s=20
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BOLT) on Wednesday reported a loss of $7.1 million in its third quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of $3.72. The results exceeded Wall Street expectations.
BOLT) on Wednesday reported a loss of $7.1 million in its third quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of $3.72. The results exceeded Wall Street expectations.
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “In
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 77.2K | $311.99K | 0.00% | Added+40.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-03-12 | -5.52 | -2.98 | +45.95% |
| 2025-11-12 | -5.39 | -3.72 | +31.05% |
| 2025-08-14 | -6.27 | -4.46 | +28.83% |
| 2025-05-12 | -7.20 | -5.80 | +19.44% |
| 2025-03-24 | -7.00 | -8.40 | -20.00% |
| 2024-11-12 | -7.90 | -8.00 | -1.27% |
| 2024-08-13 | -11.73 | -11.20 | +4.55% |
| 2024-05-14 | -10.25 | -5.60 | +45.37% |
| 2024-03-21 | -10.10 | -9.40 | +6.93% |
| 2023-11-09 | -10.45 | -8.60 | +17.70% |
| 2023-08-07 | -8.95 | -9.60 | -7.26% |
| 2023-05-11 | -10.40 | -9.00 | +13.46% |
| 2023-03-29 | -12.05 | -10.60 | +12.03% |
| 2022-11-10 | -10.80 | -11.60 | -7.41% |
| 2022-08-10 | -14.40 | -12.20 | +15.28% |
| 2022-05-12 | -14.20 | -12.80 | +9.86% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BOLT | +3.75% | +21.53% | -3.99% | -16.67% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +0.79% | +26.17% | -0.54% | -29.36% |